The medical equipment maker is set to pay as much as $925m to buy its portfolio company that will enable Novo, Merck & Co and Samsung to exit.

Lufthansa’s portfolio company TripActions has attracted $155m in series E financing co-led by Andreessen Horowitz, Addition and Elad Gil at a valuation of $5bn.

UnitedHealth Group and Merck & Co are both in line for exits as Decipher Biosciences files for a $100m initial public offering.

The Hearst Ventures-backed 3D printing marketplace has been acquired by its digital manufacturing services peer Proto Labs in a deal potentially worth $330m.

Yale-linked Vera has rebranded from Trucode Gene Repair and will use the money to move towards clinical trials.

Vera has picked up series C cash from investors including GV and Alexandria Venture Investments to help progress its Merck Group-licensed autoimmune disease drug candidate through clinical trials.

Rich Products, Thai Union and OurCrowd have participated in a new round of convertible note financing for BlueNalu, which is developing lab-grown seafood products.

Musashi Seimitsu Industry has led a round that will support development of a proof-of-concept for KeraCel's 3D printing technology.

Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.

Novo and Pfizer are among the investors set to exit the Stanford spinout, which has set a $100m target for its initial public offering.